AstraZeneca Strengthens Partnership with Cellectis in Cell and Gene Therapy Advancement

1. AstraZeneca, a multinational pharmaceutical and biotechnology company, has increased its stake in Cellectis, a biotechnology firm specializing in gene editing and cell therapy.
2. The move is part of a broader strategic partnership between the two companies aimed at advancing the discovery and development of cell and gene therapies.
3. The collaboration will leverage Cellectis' proprietary gene-editing technology, known as TALEN, and AstraZeneca's expertise in therapeutic development and commercialization.
4. The partnership is expected to accelerate the development of innovative treatments for a range of diseases, including cancer and inherited genetic disorders.
5. The financial terms of the deal have not been disclosed, but AstraZeneca's increased stake in Cellectis underscores its commitment to investing in cutting-edge biotechnology and healthcare innovation.
6. The partnership is a significant development in the rapidly evolving field of cell and gene therapy, which holds great promise for transforming the way many diseases are treated.